Company Overview and News

 
Energy unit boosts Lopez Holdings’ second-quarter earnings

2018-08-14 bworldonline
LOPEZ Holdings Corp. reported a net income of P1.03 billion in the second quarter, higher by 43% compared with year ago’s P721-million profit attributable to the equity holders of the parent firm, with the stable showing of its energy unit boosting the quarterly results.
FPHPC FSGCF FGENG FGENF MER FGEN FSGCY LPZ FPHP FPH

 
Lopez Holdings Q2 earnings surge by 43%

2018-08-14 bworldonline
Lopez Holdings Corp. reported a net income of P1.03 billion in the second quarter, higher by 43% compared with year ago’s P721-million profit attributable to the equity holders of the parent firm, with the stable showing of its energy unit boosting the quarterly results.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH

5
Flat trades expected in face of MSCI rebalancing

2018-05-27 bworldonline
SHARE PRICES are seen to move sideways this week as investors anticipate MSCI’s rebalancing and window dressing toward the end of the month.
PSKXF LPZ PHSXY PSE

12
Stock index rallies to 7,800

2018-05-15 business.inquirer.net
The local stock barometer rallied to the 7,800 level on Tuesday, perked up by the latest rebalancing of the closely tracked MSCI indices.
SMIVY PSKXF SVTMF LPZ PHSXY SM PSE LTG

51
Conglomerates deliver mixed Q1 results, but outlook remains positive

2018-05-15 bworldonline
CONGLOMERATES are expected to register better financial results this year, as the country’s top firms proceed with expansion programs amid a new tax regime and challenges in their respective businesses.
JGSMY GTCAP GTCXY SVTMF SMCP1 JGS SM AEV SMGBF SMIVY SMC ALGGY MPCFF PHSXY PSE AGI JGSHF DMC PSKXF MPCIY LPZ DMCIF SMGBY DMCP SMC2B SMC2A SMC2D SMC2C ABTZY MPI SMC2F SMC2E ALGGF DMCHY LTG

6
Shares up on continued optimism after BSP move

2018-05-15 bworldonline
STOCKS JUMPED on Tuesday as investors remained optimistic on the rate hike implemented by the central bank last week.
SMPH LPZ SPHXY SPHXF SPHZF

5
PSEi back to 7,800

2018-05-15 business.inquirer.net
The local stock barometer rallied to the 7,800 level on Tuesday, perked up by the latest rebalancing of the closely-tracked MSCI indices.
PSKXF LPZ PHSXY PSE

 
IMI, MAC join MSCI Small Cap Index

2018-05-15 business.inquirer.net
IMI COO Gilles Bernard announces nearing completion of IMI’s facility in Serbia, its 20th factory across the globe
LPZ

1
Lopez nets P1.14B

2018-05-14 business.inquirer.net
Conglomerate Lopez Holdings booked a 10-percent year-on-year increase in first quarter net profit to P1.14 billion, backed by a double-digit growth in earnings from its power generation and broadcasting businesses.
FPHPC LPZ FPHP FPH

2
Lopez Holdings 2017 profit down 36%

2018-04-17 business.inquirer.net
Conglomerate Lopez Holdings posted a net profit of P4.22 billion last year, down by 36 percent in the absence of one-off gains and election season-related surge in media advertising revenue that jacked up its bottom line in 2016.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH

2
Lopez Holdings income declines 36% in 2017

2018-04-17 bworldonline
THE absence of one-time gains that inflated profits in 2016 dragged earnings Lopez Holdings, Inc. last year.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH

2
Lopez Holdings 2017 profits down on lack of one-time gains

2018-04-17 bworldonline
The absence of one-time gains that inflated profits in 2016 dragged earnings of Lopez Holdings, Inc. last year.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH

9
Stocks decline to track Wall Street on Tillerson

2018-03-14 bworldonline
SHARES fell on Wednesday as the lack of catalysts in the local front, alongside tensions in the United States’ political scene, continued to put pressure on regional markets.
JGSMY PSKXF JGS LPZ PHSXY PSE JGSHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:LPZ / Lopez Holdings Corporation on message board site Silicon Investor.

Colossal Resources - CLPZF - Colbalt in Zambia Colossal Resources - CLPZF - Colbalt in Zambia Colossal Resources - CLPZF - Colbalt in Zambia Colossal Res.-CLPZF-major internet deal announcement Colossal Res.-CLPZF-major internet deal announcement Colossal Res.-CLPZF-major internet deal announcement